Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.

Frontiers in immunology - 1 Jan 2021

Ye Ting, Zhang Jie-Ying, Liu Xin-Yi, Zhou Yu-Han, Yuan Si-Yue, Yang Meng-Mei, Xie Wen-Zhuan, Gao Chan, Chen Yao-Xu, Huang Meng-Li, Ye Cheng-Zhi, Chen Jing

Abstract excerpt

Background: MAP2K1/2 genes are mutated in approximately 8% of melanoma patients; however, the impact of MAP2K1/2 gene alterations on the efficiency of immunotherapy has not been clarified. This study focused on the correlation between MAP2K1/2 gene mutations and the treatment response. Methods: Six metastatic melanoma clinical cohorts treated with immune checkpoint inhibitors [anti-cytotoxic T lymphocyte...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy
Share to MAP Kinase Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 2

Share to Melanoma

Share to Mutation

Share to Progression-Free Survival

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 35069558
DOI: 10.3389/fimmu.2021.785526
PMCID: PMC8770828

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.PMID 35069558Read ↗

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma.Semantic proximity Read ↗

Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment : Author List.Semantic proximity Read ↗

Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.Semantic proximity Read ↗

Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous MelanomaSemantic proximity Read ↗

Mutated Processes Predict Immune Checkpoint Inhibitor Therapy Benefit in Metastatic MelanomaSemantic proximity Read ↗

Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.Semantic proximity Read ↗

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.Semantic proximity Read ↗

Melanoma Treatments: Advances and Mechanisms.Semantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSemantic proximity Read ↗

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung CancerSemantic proximity Read ↗

Genetic basis for clinical response to CTLA-4 blockade in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.